A detailed history of Core Alternative Capital transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Core Alternative Capital holds 43 shares of REGN stock, worth $30,817. This represents 0.01% of its overall portfolio holdings.

Number of Shares
43
Previous 43 -0.0%
Holding current value
$30,817
Previous $45,000 -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$902.69 - $993.35 $10,832 - $11,920
-12 Reduced 21.82%
43 $41,000
Q4 2023

Feb 14, 2024

SELL
$775.18 - $881.7 $4,651 - $5,290
-6 Reduced 9.84%
55 $48,000
Q2 2023

Jul 27, 2023

BUY
$700.03 - $830.35 $1,400 - $1,660
2 Added 3.39%
61 $43,000
Q1 2023

Apr 18, 2023

BUY
$680.49 - $826.97 $5,443 - $6,615
8 Added 15.69%
59 $48,000
Q4 2022

Jan 31, 2023

BUY
$705.89 - $766.39 $705 - $766
1 Added 2.0%
51 $36,000
Q3 2022

Oct 18, 2022

BUY
$573.97 - $724.32 $1,721 - $2,172
3 Added 6.38%
50 $34,000
Q2 2022

Aug 01, 2022

BUY
$548.35 - $738.84 $6,031 - $8,127
11 Added 30.56%
47 $28,000
Q1 2022

May 10, 2022

BUY
$595.12 - $698.43 $19,043 - $22,349
32 Added 800.0%
36 $25,000
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $2,173 - $2,683
4 New
4 $3,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.8B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Core Alternative Capital Portfolio

Follow Core Alternative Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Alternative Capital, based on Form 13F filings with the SEC.

News

Stay updated on Core Alternative Capital with notifications on news.